Find information on Industry Analysis Report

Posts tagged ‘Healthcare’

Western Europe In Vitro Diagnostics Market at a glance

Bharatbook.com included a new research report on “Western Europe (EU-16) In Vitro Diagnostics Market Report & Forecast (2012 – 2015)” into its market report catalogue for reselling.

Western Europe (EU-16) In Vitro Diagnostics Market Report & Forecast (2012 – 2015)

In Western Europe (EU-16) countries major portion of healthcare is borne by the government. These Western Europe (EU-16) countries spend 9 to 11% of their GDP on the healthcare of its citizens. So the recent Euro zone crisis has hardly hit the In Vitro Diagnostics (IVD) market for the year 2011 and 2012. But from 2013 the growth for In Vitro Diagnostics (IVD) industry is expected to be back on track. Western Europe (EU-16) In Vitro Diagnostics (IVD) market is one of the biggest markets globally. Western Europe (EU-16) In Vitro Diagnostics (IVD) market is expected to be more than Euro 11 Billion by 2015.  http://www.bharatbook.com/medical-devices-market-research-reports/western-europe-eu-16in-vitro-diagnostics-market-report-forecast-2012-2015.html

Germany, France and Italy are three biggest markets in Western European (EU-16) countries. Germany controls the biggest market share closely followed by France and Italy in 2011. Together these three countries controls 58.5% market share for the year 2011. From our research we found that only two countries out of 16 countries studied in this report is expected to show a contraction in In Vitro Diagnostics (IVD) market for the year 2012. Whereas rest of the Western Europe (EU-16) countries will either grow marginal or will show no growth for the year 2012. However from 2013 every country is expected to back on track and expected to grow.

“Western Europe (EU-16) In Vitro Diagnostics Market Report & Forecast (2012 – 2015)” provides a comprehensive assessment of the 16 Western European countries In Vitro Diagnostics (IVD) market scenario and its forecast. The report also provides market landscape and market share information in the Western Europe (EU-16) IVD market. The report also entails major drivers and challenges of Western Europe (EU-16) In Vitro Diagnostics market.

Countries Analyzed in this Report
Germany, France, Italy, United Kingdom, Spain, Netherlands, Greece, Portugal, Belgium, Sweden, Austria, Denmark, Finland, Ireland, Switzerland, Norway

Key Topics Covered in the Report

• Western Europe (EU-16) In Vitro Diagnostics Market Performance (2005 – 2011)
• Western Europe (EU-16) In Vitro Diagnostics Market Forecast (2012 – 2015)
• Western Europe (EU-16) In Vitro Diagnostics Market Share (Country wise) (2009 – 2011)
• Western Europe (EU-16) In Vitro Diagnostics Market Share Forecast (Country wise) (2012 – 2015)
• Western Europe (EU-16) Market Performance of In Vitro Diagnostics Market for Each Country (2002 – 2011)
• Western Europe (EU-16) Market Forecast of In Vitro Diagnostics Market for Each Country (2012 – 2015)
• Drivers and Challenges for Western Europe (EU-16) In Vitro Diagnostics Market

For more information kindly visit : http://www.bharatbook.com/medical-devices-market-research-reports/western-europe-eu-16in-vitro-diagnostics-market-report-forecast-2012-2015.html

Contact us at :

Bharat Book Bureau
Ph.: + 91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs : https://bharatbookblog.wordpress.com/

Asia Medical Tourism Analysis and Forecast Seems to be Bright

Bharatbook.com included a new research report on “Asia Medical Tourism Analysis and Forecast to 2015” provides the current status and future outlook of Asia medical tourism market survey analysis.

Asia Medical Tourism Analysis and Forecast to 2015

In this global economic slowdown when every other industry future seems bleak. Medical Tourism Industry is the one sector whose present is bright and future seems even brighter. Asia is one of the first regions in the world to promote medical tourism and has created a brand name for itself for having affordable and high quality healthcare. Asia medical tourist number of arrivals is expected to cross the figure of 10 Million numbers by 2015. Asia medical tourism market is expected to double by 2015 from its current market in 2011. In our research of medical tourism analysis we found that out of 7 countries 3 countries Thailand, India and Singapore is expected to control more than 80% market share in 2015. http://www.bharatbook.com/healthcare-market-research-reports/asia-medical-tourism-analysis-and-forecast-to-2015.html

Thailand is the leader in medical tourist arrivals holding more than 40% share in Asia medical tourist arrivals in 2011. Its medical tourism market is also expected to be more than double by 2015 from its current market in 2011.

India was one of the first countries to recognize the potential of medical tourism. From the year 2009 to 2011 the number of medical tourists in India has grown by 30%. It is estimated that by the year 2015, India will receive nearly half a Million medical tourists annually.

Singapore medical facilities are considered to be the best in Asia but its treatment cost are bit costlier compared to its competitors. Singapore medical tourist arrivals are expected to be more than 1 Million by 2015.

Philippines started off bit late for the medical tourism but are catching up quickly. Its medical tourism market is expected to grow with a CAGR of 9% for the period of 2012 – 2015.

South Korea is a fast-growing medical tourism destination. It is forecasted that by 2015, South Korea will attract more than 300 Thousand medical tourists.

Malaysia has seen an impressive growth in medical tourism industry. Malaysia medical tourism market has grown more than 8 times in 2011 compared to its market in 2003.

Taiwan medical tourism has become one of the biggest attractions for mid to high income Chinese tourists. The country’s medical tourism market is expected to increase at 7% CAGR from 2012 to 2015.

“Asia Medical Tourism Analysis and Forecast to 2015” provides the current status and future outlook of Asia medical tourism market survey analysis. This report studies in detail various aspects of medical tourism such as number of foreign patients’ arrivals, revenue from foreign patients change projections and cost comparison of various types of surgeries in the United States with other Asian countries (Thailand, India, Singapore, Malaysia, Philippines, South Korea and Taiwan). The medical tourists arrivals share and medical tourism market share has also been studied in this report. Driving forces of each country in medical tourism industry and Challenges faced by each country in medical tourism industry has been studied in this report.

7 Asian Countries Medical Tourism Analysis Data Studied in this Report

India, Thailand, Singapore, Malaysia, Philippines, South Korea and Taiwan

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/asia-medical-tourism-analysis-and-forecast-to-2015.html

Contact us at :

Bharat Book Bureau
Ph.: + 91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs : https://bharatbookblog.wordpress.com/

Pet Care in India

Bharat Book introduces a report ” Pet Care in India ”  Pet Care in India industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Business Report

Essential resource for top-line data and analysis covering the India pet care market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/pet-care-in-india.html

Summary:

The pet care market consists of the retail sales of cat care, dog care, other pet care and pet healthcare products. The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the compilation of this report have been calculated using 2010 annual average exchange rates.


Highlights

The Indian pet care market generated total revenues of $57.3 million in 2010, representing a compound annual growth rate (CAGR) of 9.4% for the period spanning 2006-2010.

*Pet healthcare sales proved the most lucrative for the Indian pet care market in 2010, generating total revenues of $44.3 million, equivalent to 77.3% of the market’s overall value.

*The performance of the market is forecast to accelerate, with an anticipated CAGR of 10% for the five-year period 2010-2015, which is expected to drive the market to a value of $92.5 million by the end of 2015.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pet care market in India

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pet care market in India

Leading company profiles reveal details of key pet care market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the India pet care market with five year forecasts by both value and volume

Macroeconomic indicators provide insight into general trends within the India economy

Table of Contents
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 6
Market definition 6
Market analysis 6
MARKET DATA 7
Market value 7
MARKET SEGMENTATION 8
Category segmentation 8
Geography segmentation 10
Market share 11
Market distribution 12
MARKET OUTLOOK 13
Market value forecast 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 15
Supplier power 16
New entrants 17
Threat of substitutes 18
Degree of rivalry 19
LEADING COMPANIES 20
Daivie Exports 20
Mars, Incorporated 22
Shreeji International 23
MACROECONOMIC INDICATORS 24
Country Data 24
APPENDIX 26
Methodology 26
Industry associations 27
Related MarketLine research 27

LIST OF TABLES

Table 1: India pet care market value: $ million, 2006–10 7
Table 2: India pet care market category segmentation : % share, by value, 2006 – 2010 8
Table 3: India pet care market category segmentation : $million, by value, 2006 – 2010 8
Table 4: India pet care market geography segmentation : $million, by value, 2010 10
Table 5: India pet care market share: % share, by value, 2010 11
Table 6: India pet care market distribution: % share, by value, 2010 12
Table 7: India pet care market value forecast: $ million, 2010–15 13
Table 8: Daivie Exports: key facts 20
Table 9: Mars, Incorporated: key facts 22
Table 10: Shreeji International: key facts 23
Table 11: India size of population (million), 2006–10 24
Table 12: India GDP (constant 2000 prices, $ billion), 2006–10 24
Table 13: India GDP (current prices, $ billion), 2006–10 24
Table 14: India inflation, 2006–10 25
Table 15: India consumer price index (absolute), 2006–10 25
Table 16: India exchange rate, 2006–10 25


For more information kindly visit :

Pet Care in India

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Report on Therapy Trends: Multiple Sclerosis

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
* We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
* Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
* Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
* KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
* Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
* Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring

Critical questions answered
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.

* What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes.
* How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy BG-12 is expected to usurp the current market leaders and become the first-line therapy of choice.
* How will treatment developments play out in the near future? Biogen’s activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
* Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
* Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? Pricing and safety will play a large part in determining uptake of this highly effective drug
* How will the launch of biosimilars affect prescribing behavior? Pricing will be a key determinant in positioning and uptake
* How will Novartis’s Gilenya be affected by recent safety concerns? Long-term concerns have kept it from being the first line therapy.
* Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.

For more information kindly visit :
Report on Therapy Trends: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Consensus Outlook: Multiple Sclerosis

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

* An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
* A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016
* Timely event-driven market forecast report and data analysis updates over the next 12 months

Understand the Unique Benefits of Consensus Outlook
* Evaluate future sales forecasts and predicted market growth
* Map your market parameters and chart commercial prospects
* Assess market share by company and product
* Tailor your strategic and investment focus based on the competition
* Set proactive launch and branding strategies
* Keep up with event-driven market data updates

Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
* Historical MS sales from 2006–2011
* Forecast MS sales from 2012-2016
* Key competitors and drug developers
* Predicted product positioning
* Current and late-stage pipeline drugs
* Future event mapping to forecast data points
* Comparative clinical trial results

An approach backed by unrivalled knowledge and market intimacy
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

For more information kindly visit :
Report on Consensus Outlook: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021

What are the commercial prospects for pharmaceutical anti-counterfeiting technology? Our new report shows you that industry and market’s revenue potential from 2011 to 2021.

There, you will assess anti-counterfeiting technologies, seeing trends and opportunities. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our report shows you revenue prospects for pharma anti-counterfeiting technologies at total world, submarket and national levels to 2021. We discuss the anti-counterfeiting activities of companies such as Pfizer, J&J, GSK, Sanofi-Aventis, Novartis and AstraZeneca.

We also discuss the activities and potential of anti-counterfeiting specialists, such as NanoGuardian, Ahura Scientific, TruTag Technologies, Colorcon, Authentix, 3M, Cortegra and Covectra.
Our study forecasts revenues for radio frequency identification (RFID), pharmaceutical taggant, hologram/OVD, security ink and watermark technologies to 2021. You will see their market potentials.
Which pharma anti-counterfeiting technologies and national markets will provide the best opportunities from 2011 to 2021? What effects will governmental policies have? Our work gives answers you need.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work – so you won’t be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP analysis, review of companies and product developments, and opinions from our survey.
We include 67 tables and charts and three research interviews (shown in the accompanying lists). Our study helps you to understand pharma anti-counterfeiting activities this decade.
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the pharmaceutical anti-counterfeiting industry and market from 2010 to 2021
• You will discover revenue forecasting for the overall world market to 2021
• You will see revenue predictions for leading technologies – RFID, taggants, holograms/OVDs, security inks and watermarks – to 2021
• You will assess anti-counterfeiting needs at world and regional level
• You will find revenue predictions for leading geographical markets to 2021 (US, UK, Germany, France, Japan, Italy, Canada, Spain, China and India)
• You will assess the implications of government mandates for product serialisation, seeing how these will affect the activities of pharma companies
• You will assess leading companies in pharma anti-counterfeiting, discovering their activities, potential and commercial outlooks for the future
• You will examine research and development, as well as up-and-coming technologies for tackling drug counterfeiting
• You will investigate competition and opportunities that will influence revenues
• You will see what will stimulate and restrain the industry and market
• You will analyse opportunities for established companies and those seeking to enter the anti-counterfeiting technologies market
• You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in pharmaceutical anti-counterfeiting technologies. We give predictions and answers you need. Don’t miss out – please order our report now.

For more information kindly visit :
Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on 2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry was professional and depth research report on China Synthesis Polypeptide Drug industry. The report firstly introduced Synthesis Polypeptide Drug basic information included Synthesis Polypeptide Drug definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Synthesis Polypeptide Drug industry policy and plan, Synthesis Polypeptide Drug product specification, manufacturing process, product cost structure etc. then statistics China key manufacturers Synthesis Polypeptide Drug capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Synthesis Polypeptide Drug products customers application capacity market position company contact information etc company related information, then collect all these manufacturers data and listed China Synthesis Polypeptide Drug capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced China Synthesis Polypeptide Drug 2009-2013 capacity production price cost profit production value gross margin etc information. http://www.bharatbook.com/healthcare-market-research-reports/2012-deep-research-report-on-global-and-china-synthesis-polypeptide-drug-industry.html

And also listed Synthesis Polypeptide Drug upstream raw materials equipments and Sharp Solarnstream clients alternative products survey analysis and Synthesis Polypeptide Drug marketing channels industry development trend and proposals. In the end, this report introduced Synthesis Polypeptide Drug new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis of China Synthesis Polypeptide Drug industry. In a word, it was a depth research report on China Synthesis Polypeptide Drug industry. And thanks to the support and assistance from Synthesis Polypeptide Drug industry chain related technical experts and marketing engineers during Research Team survey and interviews.

Table of Contents
Chapter One Synthesis Polypeptide Drug Industry Overview 1
1.1 Synthesis Polypeptide Drug Definition 1
1.2 Synthesis Polypeptide Drug Classification and Application 3
1.3 Professional Terms Interpretation 8
1.4 Synthesis Polypeptide Drug Industry Chain Structure 12
1.5 Synthesis Polypeptide Drug Industry Overview 14

Chapter Two Synthesis Polypeptide Drug International and China Market Analysis 16
2.1 Synthesis Polypeptide Drug Industry International Market Analysis 16
2.1.1 Synthesis Polypeptide Drug International Market Development History 16
2.1.2 Synthesis Polypeptide Drug Product and Technology Developments 18
2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 25
2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status 28
2.1.5 Synthesis Polypeptide Drug International Market Development Trend 30
2.2 Synthesis Polypeptide Drug China Market Analysis 33
2.2.1 Synthesis Polypeptide Drug China Market Development History 33
2.2.2 Synthesis Polypeptide Drug Product and Technology Developments 33
2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis 35
2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status 37
2.2.5 Synthesis Polypeptide Drug China Market Development Trend 37
2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis 42

Chapter Three Major Synthesis Polypeptide Drug Analysis 43
3.1 Immunity Regulating Medicine (Allergy Infection and Immune) 43
3.1.1 Glatiramer Injection (Glatiramer Acetate) 43
3.1.2 Thymalfasin for Injection 46
3.1.3 Thymopentin Injection 49
3.1.4 Thymopetidum Injection 53
3.1.5 Summary 55
3.2 Digestive System Drugs (Gastrointestinal Type) 57
3.2.1 Octreotide Acetate Injection 57
3.2.2 Somatostatin for Injection 61
3.3 Bone and Connective Tissue Types (Thyroid hormones Drug) 66
3.3.1 Salmon Calcitonin Injection 67
3.3.2 Elcatonin Injection 70
3.3.4 TerfparaLide Injectlon 72
3.4 Gynecologic or Obstetric Drug 76
3.4.1 Oxytocin Injection 76
3.4.2 Carbetocin Injection 81
3.4.3 Acetate Atosiban Injection 83
3.5 Tumor Drug (hCG) 86
3.5.1 Leuprorelin Acetate Microspheres for Injection 87
3.5.2 Goserelin Acetate 89
3.5.3 Triptorelin Acetate Injection 92
3.5.4 Chorionic Gonadotrophin for Injection 95
3.6 Urinary System Drug (Diabetes Insipidus) 98
3.6.1 Desmopressin Acetate Injection 98
3.6.2 Terlipressin for Injection 101
3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents) 105
3.7.1 Biosynthetic Glucagon for Injection 105
3.7.2 Exenatide Injection 106

For more information kindly visit :
Report on 2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Tag Cloud